OVID (Ovid Therapeutics) Marketable Securities: $61.46 Mil (As of Mar. 2026)


OVID Ovid Therapeutics Inc OVID
48 GF Score
Price $2.69
GF Value $8.37
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Ovid Therapeutics Marketable Securities?

Ovid Therapeutics OVID +0.75% 48 Marketable Securities is $61.46 Mil as of Mar. 2026. GuruFocus rates OVID with a GF Score™ of 48/100 and a GF Value™ of $8.37 (Possible Value Trap). The stock has 6 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Ovid Therapeutics's Marketable Securities for the quarter that ended in Mar. 2026 was $61.46 Mil.

Ovid Therapeutics's annual Marketable Securities declined from Dec. 2023 ($78.79 Mil) to Dec. 2024 ($26.77 Mil) but then increased from Dec. 2024 ($26.77 Mil) to Dec. 2025 ($56.48 Mil).

Ovid Therapeutics  (NAS:OVID) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Ovid Therapeutics Marketable Securities Related Terms

Ovid Therapeutics Marketable Securities Historical Data

* Premium members only.

The historical data trend for Ovid Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ovid Therapeutics Marketable Securities Chart

Ovid Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 84.13 78.79 26.77 56.48

Ovid Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.86 9.93 4.99 56.48 61.46
OVID
48GF Score
Ovid Therapeutics Inc OVID
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ovid Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $61.46 Mil mean?
Ovid Therapeutics (OVID) has a Marketable Securities of $61.46 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Ovid Therapeutics and its competitors.
Is Ovid Therapeutics' Marketable Securities too high?
Ovid Therapeutics' current Marketable Securities is $61.46 Mil. Overall, Ovid Therapeutics has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ovid Therapeutics' Marketable Securities compare to ARTV and CCCC?
Ovid Therapeutics' Marketable Securities of $61.46 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Ovid Therapeutics and its competitors. Ovid Therapeutics's current Marketable Securities is $61.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ovid Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ovid Therapeutics (OVID) is currently considered Possible Value Trap. The stock's GF Value™ is $8.37, compared to a current price of $2.69 — trading 67.9% below its estimated fair value. The current Marketable Securities is $61.46 Mil. Ovid Therapeutics' overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Ovid Therapeutics (OVID), the current Marketable Securities is $61.46 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ovid Therapeutics (OVID) Overvalued in 2026?

Based on GuruFocus' analysis, Ovid Therapeutics stock appears to be undervalued. The current stock price of $2.69 is trading 67.9% below its estimated GF Value™ of $8.37. GuruFocus considers Ovid Therapeutics to be Possible Value Trap.

Key valuation signals for OVID:

  • Marketable Securities: $61.46 Mil
  • GF Value™: $8.37 vs. price of $2.69 (67.9% below fair value)
  • GF Score™: 48/100 with 6 warning signs

No single metric tells the full story. See the OVID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ovid Therapeutics Business Description

Other Exchanges 1OT:Germany
Address 441 Ninth Avenue, 14th Floor, New York, NY, USA, 10001
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
48GF Score

Get the complete analysis for OVID

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.69
Price
$8.37
GF Value